Few advancements in contemporary medicine have sparked as much enthusiasm and potential as CAR T-cell therapy.

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy.

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg ... hepatocytes in human-liver-chimeric mice. E6F6-based immunotherapy facilitated the ...

During CAR T-cell therapy, T-cells are extracted and modified to add a receptor to their surface. This helps the T-cells better recognize and destroy cancer cells when they’re reintroduced into ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...